Gentiva Health (UNKNOWN:GTIV.DL) shareholders got some welcome news yesterday, as shares gained 62% in the wake of Kindred Health's (NYSE:KND) announcement that it was taking its bid to acquire the company hostile.

So, good news on the price side, and the deal obviously makes sense from Kindred's perspective. But what about Gentiva's? Should shareholders support this deal for the opportunity to diversify away from government payers? Or should they support management, which claims that its "strategy as a stand-alone company will generate substantially more value to our shareholders"?

In this video, from Thursday's Market Checkup, the Motley Fool's health care focused show, health care analysts Michael Douglass and David Williamson consider the potential benefits to Gentiva and whether this is a good deal for shareholders.

David WilliamsonMichael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.